Reduction in tumor IFP in animal and human tumors after antiangiogenic treatment
| IFP before treatment (mean ± SE, mm Hg) | IFP after treatment (mean ± SE, mm Hg) | Ref. | |
|---|---|---|---|
| IFP in human tumors | |||
| Rectal carcinoma treated with 5 mg/kg bevacizumab | 15 ± 0.50 (n = 4) | 4 ± 0.55 (n = 4) | ( 27) |
| Rectal carcinoma treated with 10 mg/kg bevacizumab | 15.8 ± 2.0 (n = 5) | 5.4 ± 0.85 (n = 5) | ( 29) |
| IFP in animal models | |||
| Spontaneous tumor grown in C3H mice treated with DC101 | 11.4 ± 0.55 (n = 4) | 4.63 ± 0.50 (n = 4) | ( 52) |
| MCaIV murine mammary carcinoma treated with DC101 | 6.13 ± 1.0 (n = 5) | 3.10 ± 0.52 (n = 5) | ( 26) |
| 54A human small cell lung carcinoma xenograft treated with DC101 | 12.03 ± 2.29 (n = 5) | 6.2 ± 0.97 (n = 5) | ( 26) |
| U87 human glioblastoma xenograft treated with DC101 | 11.52 ± 1.89 (n = 5) | 5.95 ± 1.06 (n = 5) | ( 26) |
| LS174T human colon adenocarcinoma xenograft treated with bevacizumab | 13.5 ± 4.0 (n = 8) | 3.5 ± 1.0 (n = 8) | ( 25) |
| U87 human glioblastoma xenograft treated with bevacizumab | 12.0 ± 3.0 (n = 8) | 3.0 ± 1.5 (n = 8) | ( 25) |